The use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the first line treatment for EGFR-mutant advanced non-small cell lung cancer (NSCLC), but drug resistance will be acquired within 1-2 years, and the following treatment efficacy is poor. The invention of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors has dramatically changed the situation of tumor treatment. PD-1/PD-L1 inhibitors are less effective in patients with NSCLC harboring EGFR mutation. It is a challenge to make patients with EGFR-mutated advanced NSCLC benefit from anti-PD-1/PD-L1 therapy. In this paper, the research progress on the impact of EGFR mutation on the immune status of NSCLC and related clinical studies in recent 5 years are reviewed. .
【中文题目：EGFR突变的晚期非小细胞肺癌的 抗PD-1/PD-L1治疗研究进展】 【中文摘要：表皮生长因子受体（epidermal growth factor receptor, EGFR）酪氨酸激酶抑制剂（tyrosine kinase inhibitor, TKI）是EGFR突变的晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）的一线治疗方案，但1年-2年内会出现耐药，后续治疗效果差。程序性死亡受体1（programmed cell death 1, PD-1）/程序性死亡配体1（programmed cell death ligand 1, PD-L1）抑制剂的出现极大地改变了肿瘤治疗的格局。然而，单药抗PD-1/PD-L1对EGFR突变的晚期NSCLC低应答或无应答，如何使EGFR突变的晚期NSCLC患者从抗PD-1/PD-L1治疗中获益是需要攻克的难关。本文主要就近5年来EGFR突变对NSCLC免疫状态影响的研究进展及相关的临床研究进行综述。 】 【中文关键词：肺肿瘤；免疫治疗；肿瘤微环境】.
Keywords: Immune therapy; Lung neoplasms; Tumor microenvironment.